December 10th, 2019, Venues Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company”) (stock code: 2500.HK) successfully listed on Hong Kong stock exchange main board. CMBI acted as Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager for Venus Medtech’ H-Shares IPO.
Venues Medtech is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. According to Frost & Sullivan, the Company had a 79.3% market share in China by implantation volume of TAVR products in 2018. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the NMPA and commercialized in China. As the pioneer in the transcatheter heart valve industry in China, the Company enjoys first mover advantages. The Company believes that its first mover advantages, together with its comprehensive product pipeline covering all four heart valves, robust intellectual property portfolio with 193 issued patents and 196 patent applications as of the Latest Practicable Date, and visionary management team, will serve as high entry barriers and differentiate itself from its peers.
Venus Medtech issued 78,537,500 new H shares in the global offering and was priced at HK$33.00 per share, with total proceeds being HK$2.59 billion (assuming Over-Allotment Option is not exercised). The book was multiple times covered with a good mixed of investors. The international offering was over-subscribed because of the Company's excellent fundamentals and attractive pricing level.
As the Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager in this project, CMBI played an important role in deal execution, marketing and sales. Leveraging strong network of Sovereign wealth funds, Chinese investors and high net-worth individuals, CMBI assisted the Company in introducing many long-term, high quality and low price-sensitive investors, which has made an important contribution to successful listing of Venus Medtech.